Morepen Laboratories Ltd. — Call Transcript 2019

May 6, 2019

==> picture [177 x 84] intentionally omitted <==

Morepen Laboratories Ltd. is one of India’s leading API & Health Care diagnostics manufacturer. The company will be hosting a conference call for investors and analyst community on Wednesday, 8[th ] May, 2019 at 04.00 P.M. (IST)

The call will be initiated with a brief management discussion on the company, business segments and earnings performance followed by an interactive question and answer session.

On behalf of the company the call will addressed by:

• Mr Sushil Suri : Chairman and Managing Director

  • Mr Ajay Sharma : Chief Financial Officer

Details of the conference call are as follows:

– Wednesday, 8[th] May 2019 04.00 P.M. (IST)

Conference Dial‐In Numbers	Conference Dial‐In Numbers
Mumbai (Primary No.)	+91 22- 62801239
Universal Access	022- 7115 8140
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448

Note: When using dial‐in numbers mentioned below please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time.

=============================================================

About Morepen Laboratories Limited

Morepen Laboratories Ltd. (Morepen) is a 35‐year old, around Rs. 800 Cr. pharmaceutical and healthcare products company. The company went public in the year 1993 and is currently listed at both the Bombay Stock Exchange as well as the National Stock Exchange.

Morepen is engaged in the manufacturing and sale of APIs/ Bulk Drugs, Home Diagnostics, Formulations and OTC products. The company's state‐of‐the‐art manufacturing facility at Baddi (Himachal Pradesh) comprises a scientifically integrated complex of 10 plants, each with a specific product profile.

The USFDA approved plant at Masulkhana is for manufacture of Loratadine, an antiallergy drug ‐ internationally known as Claritin. Desloratadine and the new blockbuster drug Montelukast is also manufactured at this FDA approved site. The large and spread out manufacturing facility at Baddi has EU GMP & WHO GMP Standards and manufactures latest and much in demand APIs like

Atorvastatin, Rosuvastatin, Fexofenadine and others for regulated markets of Europe, USA and also for non‐regulated markets across the globe.

Morepen markets over 100 branded formulations under six major therapeutic segments in the domestic market. The company's manufacturing facilities are backed by a strong dedicated team of research and development (R&D) professionals who ensure stringent quality standards. In Home ‐ Diagnostics business, Morepen has a formidable presence in Blood Glucose Monitors and Blood Pressure Monitors, in the domestic markets. The company's OTC brands are being promoted under its wholly owned subsidiary Dr. Morepen Limited. Dr. Morepen's famous OTC product line, including Burnol, Lemolate, Sat‐lsabgol, Pain‐X and others, has a significant presence in the domestic market.

For any further information please contact

Mr. Sonal Kumar Shrivastava Kirin Advisors Ph -9324748334 Email: sonalkumar@kirinadvisors.com

DISCLAIMER:

Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and abroad. Actual results might differ substantially from those expressed or implied. Morepen Laboratories Ltd and its Management will not be in any way responsible for any action taken based on such statements and discussions. Morepen also undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.